The theory was vividly validated in our clinical cohort, as DLBCL patients with concurrent PI3K activation and IQGAP3 upregulation actually had an exceptionally excellent survival outcome. The gene discussed is PIK3CD; the disease is diffuse large B-cell lymphoma.